Education
About Us
Working with TipRanks
Follow Us
Progyny, Inc. (PGNY)
:PGNY
PGNY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$13.39 - $38.98
Previous CloseN/A
Volume466.97K
Average Volume (3M)1.94M
Market Cap
$1.84B
Enterprise Value$1.36B
Total Cash (Recent Filing)$114.96M
Total Debt (Recent Filing)$19.29M
Price to Earnings (P/E)38.0
Beta0.98
Next Earnings
May 07, 2025EPS Estimate
0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.56
Shares Outstanding85,413,284
10 Day Avg. Volume1,950,712
30 Day Avg. Volume1,940,109
Financial Highlights & Ratios
PEG Ratio3.85
Price to Book (P/B)N/A
Price to Sales (P/S)1.60
Price to Cash Flow (P/CF)9.00
P/FCF Ratio9.30
Enterprise Value/Market Cap0.74
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.35
Enterprise Value/Ebitda19.68
Forecast
1Y Price Target
$27.00Price Target Upside25.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
---
Bulls Say, Bears Say
Bulls Say
Financial PerformancePGNY slightly outperformed its quarterly guidance with a pre-announcement and then meaningfully outperformed the pre-announcement.
Market PositionProgyny appears to have strong traction as a category leader in a high demand space in fertility and women's health, and has a solid roadmap to make the offering stronger.
Revenue GrowthThe FY25 revenue guidance came in comfortably above, pointing to expectations for better utilization trends.
Bears Say
Competitive EnvironmentConcerns exist about the competitive environment and a lack of visibility despite increased estimates.
Customer LossThe Amazon customer loss continues to create some noise, contributing an estimated $37 to $40 million of revenue in the first half of 2025, impacting 1Q guidance.
Earnings GuidanceImplied adjusted EBITDA margin guidance is a little light versus estimates and consensus with the 16% midpoint a percentage point below FY24 margin of 17%.
---
Ownership Overview
8.19% Insiders
24.97% Mutual Funds
0.28% Other Institutional Investors
34.86% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PGNY FAQ
What was Progyny, Inc.’s price range in the past 12 months?
Progyny, Inc. lowest stock price was $13.39 and its highest was $38.98 in the past 12 months.
What is Progyny, Inc.’s market cap?
Progyny, Inc.’s market cap is $1.84B.
When is Progyny, Inc.’s upcoming earnings report date?
Progyny, Inc.’s upcoming earnings report date is May 07, 2025 which is in 41 days.
How were Progyny, Inc.’s earnings last quarter?
Progyny, Inc. released its earnings results on Feb 27, 2025. The company reported $0.12 earnings per share for the quarter, beating the consensus estimate of $0.096 by $0.024.
Is Progyny, Inc. overvalued?
According to Wall Street analysts Progyny, Inc.’s price is currently Undervalued.
Does Progyny, Inc. pay dividends?
Progyny, Inc. does not currently pay dividends.
What is Progyny, Inc.’s EPS estimate?
Progyny, Inc.’s EPS estimate is 0.18.
How many shares outstanding does Progyny, Inc. have?
Progyny, Inc. has 85,413,284 shares outstanding.
What happened to Progyny, Inc.’s price movement after its last earnings report?
Progyny, Inc. reported an EPS of $0.12 in its last earnings report, beating expectations of $0.096. Following the earnings report the stock price went down -1.53%.
Which hedge fund is a major shareholder of Progyny, Inc.?
Currently, no hedge funds are holding shares in PGNY
---
Progyny Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$27.00 (25.64% Upside)
$27.00 (25.64% Upside)
Blogger Sentiment
Bullish
PGNY Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 762.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $5.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.4%
Last 30 Days ▼ 10.7%
Last 30 Days ▼ 10.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-41.91%
12-Months-Change
Fundamentals
Return on Equity
11.14%
Trailing 12-Months
Asset Growth
-19.80%
Trailing 12-Months
Company Description
Progyny, Inc.
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
---
PGNY Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive end to 2024 with strong revenue and client growth, high client retention, and successful new product launches. However, challenges include the loss of a major client, potential lower utilization rates, and increased investments impacting margins. Overall, the highlights outweigh the lowlights, indicating a positive outlook despite some hurdles.Read More>---
PGNY Stock 12 Month Forecast
Average Price Target
$27.00
▲(25.64% Upside)
Technical Analysis
Teladoc
―
Hims & Hers Health
―
American Well
―
Clover Health Investments
―
Oscar Health
―
Best Analysts Covering PGNY
1 Year
1 Year Success Rate
7/13 ratings generated profit
1 Year Average Return
+12.76%
reiterated a buy rating last month
Copying Glen Santangelo's trades and holding each position for 1 Year would result in 53.85% of your transactions generating a profit, with an average return of +12.76% per trade.
---